Mutual Pharmaceutical Company
CompanyUnited States
Mutual Pharmaceutical Company develops one asset, approved (colchicine in Acute Gout). Mostly small molecule acting on NLRP3 inflammasome, inflammation and TUBA1A; based in the United States.
- 1
- Asset
- Furthest stage
- Approved
- 24
- Trials
- 0
- Signals
Pipeline
1Inhibits microtubule polymerization by binding tubulin, disrupting inflammasome activation and neutrophil migration.
Approved, Small molecule, NLRP3 inflammasome, Inflammation, Acute Gout, cardiovascular death
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms5
- Trials24
- Similar companies6